Seilern Investment Management Ltd Purchases 2,688 Shares of Zoetis Inc. $ZTS

Key Points

• Seilern Investment Management Ltd increased its stake in Zoetis Inc. by 4.5%, acquiring 2,688 additional shares during Q2, bringing its total to 62,637 shares valued at approximately $9.77 million.
• Several research firms have either rated or modified their stance on Zoetis, with Argus maintaining a "buy" rating at a $190 target, while Stifel Nicolaus downgraded the stock from "buy" to "hold."
• Zoetis reported a Q2 earnings beat with $1.76 EPS, surpassing analyst expectations of $1.62, alongside a year-over-year revenue increase of 4.2% to $2.46 billion.

Seilern Investment Management Ltd grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,637 shares of the company's stock after acquiring an additional 2,688 shares during the quarter. Zoetis accounts for about 0.6% of Seilern Investment Management Ltd's holdings, making the stock its 18th largest position. Seilern Investment Management Ltd's holdings in Zoetis were worth $9,768,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the company. Lindbrook Capital LLC lifted its position in shares of Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after acquiring an additional 65 shares during the period. Quotient Wealth Partners LLC lifted its position in shares of Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after acquiring an additional 72 shares during the period. Broadway Wealth Solutions Inc. lifted its position in shares of Zoetis by 4.4% during the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after buying an additional 73 shares during the period. Menard Financial Group LLC lifted its position in shares of Zoetis by 3.8% during the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock worth $305,000 after buying an additional 75 shares during the period. Finally, Anchor Investment Management LLC lifted its position in shares of Zoetis by 4.9% during the 1st quarter. Anchor Investment Management LLC now owns 1,618 shares of the company's stock worth $266,000 after buying an additional 75 shares during the period. Institutional investors own 92.80% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ZTS. Argus restated a "buy" rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Zoetis currently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Trading Down 1.5%

ZTS stock opened at $148.33 on Friday. The business has a fifty day moving average price of $152.32 and a 200 day moving average price of $157.26. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The stock has a market capitalization of $65.74 billion, a price-to-earnings ratio of 25.53, a P/E/G ratio of 2.42 and a beta of 0.89. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business's revenue was up 4.2% on a year-over-year basis. During the same period last year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.